3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
52
Brain Neoplasms
28
Glioma
22
Gliosarcoma
19
Melanoma
18
Astrocytoma
17
Central Nervous System Neoplasms
11
Oligodendroglioma
10
Neoplasms
9
Neoplasm Metastasis
8
Recurrence
6
Carcinoma, Non-Small-Cell Lung
5
Neuroblastoma
4
Lymphoma
4
Ependymoma
4
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neurologic Manifestations
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Second Primary
2
Meningeal Carcinomatosis
2
Medulloblastoma
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocytopenia
1
Tetanus
1
Spinal Cord Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Recurrent
1
Interventions
Ifosfamide
3
Etoposide
3
Thiotepa
2
Stem Cell Transplantation
2
Radiotherapy
2
Melphalan
2
Irinotecan
2
Filgrastim
2
thymoglobulin
1
temsirolimus
1
sargramostim
1
robatumumab
1
omburtamab I-131
1
fludarabine phosphate
1
etoposide phosphate
1
Valproic Acid
1
Temozolomide
1
Tacrolimus
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Neoadjuvant Therapy
1
Mycophenolic Acid
1
Microarray Analysis
1
Mesna
1
Immunohistochemistry
1
Immunoenzyme Techniques
1
Granulocyte Colony-Stimulating Factor
1
FANG vaccine
1
Doxorubicin
1
Dexrazoxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts